

August 10, 2016

Dear Manufacturers,

I am writing on behalf of Crozer-Chester Medical Center (CCMC; 340B ID DSH390180) to inform manufacturers that CCMC recently underwent an audit by the Health Resources and Services Administration (HRSA) of CCMC's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, CCMC qualified for the 340B Program as a Disproportionate Share Hospital in Upland, Pennsylvania and participated in the 340B Program from April 1, 2012 through July 1, 2016.

Through the audit process, HRSA found CCMC to have non-compliance within their 340B program and responsible for repayment as a result of the following findings:

CCMC dispensed 340B drugs to ineligible individuals as prohibited by 42 USC 256b(a)(5)(B).

CCMC did not have adequate controls in place to ensure the prevention of duplicate discounts as prohibited by 42 USC 256b(a)(5)(A).

CCMC has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from CCMC, and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter, please contact Keith Lenhart at 610-447-6268.

Sincerely,

Philip Ryan
Chief Financial Officer